OKYO Pharma Execs to Present at BTIG Biotech Conference Amid Phase 3 Trial Prep
Event summary
- OKYO Pharma execs to present at BTIG Biotech Conference on July 28-29, 2026.
- CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli MD, PhD to participate.
- Company plans to initiate global Phase 3 trial for urcosimod in NCP treatment by year-end.
- Trial will enroll approximately 111 patients evaluating single-dose regimen.
The big picture
OKYO Pharma's participation in the BTIG Biotechnology Conference comes as it prepares to initiate a pivotal Phase 3 trial for its lead candidate urcosimod. The company is positioning itself in the competitive ophthalmology space, where successful clinical outcomes could significantly enhance its valuation. Investors will be watching closely how OKYO differentiates itself from competitors in the neuropathic corneal pain treatment market.
What we're watching
- Trial Execution
- Whether OKYO can successfully initiate and complete its Phase 3 trial by year-end.
- Market Positioning
- How the company's presentation at BTIG will impact investor perception ahead of key clinical milestones.
- Regulatory Pathway
- The pace at which OKYO advances its NCP treatment through regulatory approvals.